ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Graft versus host disease (GvHD) Richtlijnen en literatuur

Richtlijnen

Er is op dit moment geen richtlijn voor GvHD.

Literatuur

  1. Filipovich AH et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12):945-956
  2. Ferrara JL et al. Graft-versus-host disease. Lancet. 2009; 373(9674):1550-1561
  3. Socie G et al. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009; 114(20):4327-4336
  4. Zeiser R et al. Pathogenesis of acute graft-versus-host disease: from intestinal microbiota alterations to donor T cell activation. Br J Haematol. 2016 Oct; 175(2):191-207
  5. Glucksberg H et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974; 18(4): 295-304
  6. Harris AC et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the mount sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016; 22(1):4-10
  7. Leisenring WM et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006; 108(2):749-755
  8. Mohty M et al. Refractory acute graf-versus-host disease: a new working definition beyond corticosteroid refractoriness. Blood 2020; 136(17):1903-1906
  9. Gale RP et al. Is there really a specific graft-versus-leukaemia effect? Bone marrow transplantation 2016; 51(11):1413-1415
  10. Ringden O et al. The allogeneic graft-versus-cancer effect. Br J Haematol 2009; 147(5):614-633
  11. Thepot S et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia 2010; 24(11):1852-1858
  12. Boyiadzis M et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clinical cancer research 2015; 21(9):2020-2028
  13. Storb R et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31(12):1530-1538
  14. Pidala J et al. The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality. Haematologica 2011; 96(11):1678-1684
  15. Lee SJ et al. Success of immunosuppressive treatments in patients with chronic graft-versus-host disease. Biol Blood Marrow Transplant 2018; 24(3):555-562
  16. Zeiser R et al. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. The New England journal of medicine 2017; 377(26):2565-2579
  17. Zeiser R et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015; 29(10):2062-2068
  18. Miklos D et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017; 130(21): 2243-2250
  19. Meier JK et al. Oral chronic graft-versus-host disease: report from the Inter­national Consensus Conference on clinical practice in cGVHD. Clin Oral Investig 2011; 15(2):127-139
  20. Marks C et al. German-Austrian-Swiss Consensus Conference on clinical practice in chronic graft-versus-host disease (GvHD): guidance for supportive therapy of chronic cutaneous and musculoskeletal GvHD. The British journal of dermatology 2011; 165(1):18-29
  21. Wolff D et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 2010; 16(12):1611-1628
  22. Wolff D et al. Consensus Conference on Clinical Practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 2011; 17(1):1-17
  23. Hildebrandt GC et al. Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD. Bone Marrow Transplant 2011; 46(10):1283-1295
  24. Dignan FL et al. Diagnosis and management of chronic graft-versus-host disease. Br J Haematol 2012; 158(1):46-61
  25. Dietrich-Ntoukas T et al. Diagnosis and treatment of ocular chronic graft-versus-host disease: report from the German-Austrian-Swiss Consensus Conference on Clinical Practice in chronic GVHD. Cornea 2012; 31(3): 299-310. doi: 10.1097/ ICO.0b013e318226bf97
  26. Filipovich AH et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11(12):945-956
  27. Carpenter PA. How I conduct a comprehensive chronic graft-versus-host disease assessment. Blood 2011; 118(10):2679-2687
  28. Jagasia MH et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant 2015; 21(3):389-401
  29. Lee SJ. Classification systems for chronic graft-versus-host disease. Blood 2017; 129(1):30-37
  30. Koc S et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 2002; 100(1):48-51
  31. Lee SJ et al. Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant 2015; 21(6):984-999
  32. Malard F. The 2026 definition of ruxolitinib refractoriness in severe acute GVHD. Bone Marrow Transplantation May 2026; doi: 10.1038/s41409-026-02917-x

 

Ga terug naar de homepage Graft versus host disease.

Ga terug naar de algemene homepage Behandelprotocollen.